IP Verse

Polynucleotides Encoding Interleukin-12 (Il12) And Uses Thereof - EP3458083

The patent EP3458083 was granted to Moderna on Nov 2, 2022. The application was originally filed on May 18, 2017 under application number EP17726458A. The patent is currently recorded with a legal status of "Revoked".

EP3458083

MODERNA
Application Number
EP17726458A
Filing Date
May 18, 2017
Status
Revoked
May 17, 2024
Grant Date
Nov 2, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BIONTECHAug 2, 2023THOMANNADMISSIBLE
BARKER BRETTELLAug 1, 2023BARKER BRETTELLADMISSIBLE

Patent Citations (154) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2016US52352-
DESCRIPTIONEP2112235
DESCRIPTIONEP2610340
DESCRIPTIONEP2610341
DESCRIPTIONUS2005032730
DESCRIPTIONUS2005059005
DESCRIPTIONUS2005261218
DESCRIPTIONUS2007048776
DESCRIPTIONUS2007117112
DESCRIPTIONUS2008046192
DESCRIPTIONUS2008076161
DESCRIPTIONUS2009092974
DESCRIPTIONUS2009093049
DESCRIPTIONUS2009131348
DESCRIPTIONUS2009226470
DESCRIPTIONUS2009263803
DESCRIPTIONUS2010120024
DESCRIPTIONUS2010129877
DESCRIPTIONUS2010286232
DESCRIPTIONUS2010293625
DESCRIPTIONUS2010323357
DESCRIPTIONUS2011065103
DESCRIPTIONUS2011082055
DESCRIPTIONUS2011086904
DESCRIPTIONUS2011124100
DESCRIPTIONUS2011171646
DESCRIPTIONUS2011281756
DESCRIPTIONUS2012053224
DESCRIPTIONUS2012195936
DESCRIPTIONUS2012214699
DESCRIPTIONUS2012263677
DESCRIPTIONUS2012264626
DESCRIPTIONUS2012283310
DESCRIPTIONUS2012309645
DESCRIPTIONUS2012316081
DESCRIPTIONUS2012329672
DESCRIPTIONUS2013017199
DESCRIPTIONUS2013042333
DESCRIPTIONUS2013053263
DESCRIPTIONUS2013053264
DESCRIPTIONUS2013059015
DESCRIPTIONUS2013115272
DESCRIPTIONUS2013177581
DESCRIPTIONUS2013183718
DESCRIPTIONUS2013195967
DESCRIPTIONUS2013259923
DESCRIPTIONUS2014020675
DESCRIPTIONUS2014029490
DESCRIPTIONUS2014200261
DESCRIPTIONUS2014206753
DESCRIPTIONUS2014228558
DESCRIPTIONUS2014341917
DESCRIPTIONUS2015079109
DESCRIPTIONUS2015307542
DESCRIPTIONUS5082767
DESCRIPTIONUS6310197
DESCRIPTIONUS6617106
DESCRIPTIONUS6849405
DESCRIPTIONUS6984720
DESCRIPTIONUS7183395
DESCRIPTIONUS7378262
DESCRIPTIONUS7384739
DESCRIPTIONUS7456273
DESCRIPTIONUS7468275
DESCRIPTIONUS7550264
DESCRIPTIONUS7561973
DESCRIPTIONUS7943743
DESCRIPTIONUS8008449
DESCRIPTIONUS8101385
DESCRIPTIONUS8126653
DESCRIPTIONUS8217149
DESCRIPTIONUS8252538
DESCRIPTIONUS8278036
DESCRIPTIONUS8367328
DESCRIPTIONUS8389210
DESCRIPTIONUS8401798
DESCRIPTIONUS8415096
DESCRIPTIONUS8519110
DESCRIPTIONUS8609089
DESCRIPTIONUS8710200
DESCRIPTIONUS8748089
DESCRIPTIONUS8835108
DESCRIPTIONUS8900587
DESCRIPTIONUS8999380
DESCRIPTIONUS9012219
DESCRIPTIONWO0018778
DESCRIPTIONWO0155369
DESCRIPTIONWO0155371
DESCRIPTIONWO2007025008
DESCRIPTIONWO2007036366
DESCRIPTIONWO2007081740
DESCRIPTIONWO2007113648
DESCRIPTIONWO2008054828
DESCRIPTIONWO2008073915
DESCRIPTIONWO2008078180
DESCRIPTIONWO2008154098
DESCRIPTIONWO2009070653
DESCRIPTIONWO2009075886
DESCRIPTIONWO2009100430
DESCRIPTIONWO2010018563
DESCRIPTIONWO2011015347
DESCRIPTIONWO2011076142
DESCRIPTIONWO2011076143
DESCRIPTIONWO2011095623
DESCRIPTIONWO2011157294
DESCRIPTIONWO2012009644
DESCRIPTIONWO2012072096
DESCRIPTIONWO2012122444
DESCRIPTIONWO2012135805
DESCRIPTIONWO2012151212
DESCRIPTIONWO2013011378
DESCRIPTIONWO2013033640
DESCRIPTIONWO2013039857
DESCRIPTIONWO2013052523
DESCRIPTIONWO2013066678
DESCRIPTIONWO2013143555
DESCRIPTIONWO2013151671
DESCRIPTIONWO2013173223
DESCRIPTIONWO2013182623
DESCRIPTIONWO2013185067
DESCRIPTIONWO2013185069
DESCRIPTIONWO2014028429
DESCRIPTIONWO2014071963
DESCRIPTIONWO2014089486
DESCRIPTIONWO2014093924
DESCRIPTIONWO2014144196
DESCRIPTIONWO2014152513
DESCRIPTIONWO2014152659
DESCRIPTIONWO2014152673
DESCRIPTIONWO2014152774
DESCRIPTIONWO2014152940
DESCRIPTIONWO2014152966
DESCRIPTIONWO2014153052
DESCRIPTIONWO2014164253
DESCRIPTIONWO2015024667
DESCRIPTIONWO2015062738
DESCRIPTIONWO2015101414
DESCRIPTIONWO2015101415
DESCRIPTIONWO2017049245
DESCRIPTIONWO9924595
EXAMINATIONWO0152874
EXAMINATIONWO2016170176
INTERNATIONAL-SEARCH-REPORTWO2010126766
INTERNATIONAL-SEARCH-REPORTWO2013053775
INTERNATIONAL-SEARCH-REPORTWO2015095249
OPPOSITIONUS2010324120
OPPOSITIONUS9192651
OPPOSITIONWO2012170930
OPPOSITIONWO2014089486
OPPOSITIONWO2014113089
OPPOSITIONWO2015061467
OPPOSITIONWO2016170176
OPPOSITIONWO2017201350
OTHERWO2016170176

Non-Patent Literature (NPL) Citations (30) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- KAUFFMAN KEVIN J ET AL, "Materials for non-viral intracellular delivery of messenger RNA therapeutics", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, (20151221), vol. 240, doi:10.1016/J.JCONREL.2015.12.032, ISSN 0168-3659, pages 227 - 234, XP029759407
EXAMINATION- K Anwer ET AL, "Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer", Gene Therapy, GB, (20091224), vol. 17, no. 3, doi:10.1038/gt.2009.159, ISSN 0969-7128, pages 360 - 369, XP055656177
EXAMINATION- Jie Chen ET AL, "Production and clinical development of nanoparticles for gene delivery", MOLECULAR THERAPY - METHODS & CLINICAL DEVELOP, GB, (20160101), vol. 3, doi:10.1038/mtm.2016.23, ISSN 2329-0501, page 16023, XP055656178
EXAMINATION- Andreas M Reichmuth ET AL, "mRNA vaccine delivery using lipid nanoparticles", Therapeutic Delivery, GB, (20160501), vol. 7, no. 5, doi:10.4155/tde-2016-0006, ISSN 2041-5990, pages 319 - 334, XP055401839
OPPOSITION- Shi Fushun, Rakhmilevich Alexander L, Heise Chuck P, Oshikawa Katsuhisa, Sondel Paul M, Yang Ning-Sun, Mahvi David M, "Intratumoral Injection of Interleukin-12 Plasmid DNA, Either Naked or in Complex with Cationic Lipid, Results in Similar Tumor Regression in a Murine Model", Molecular Cancer Therapeutics, US , (20020901), vol. 1, no. 11, ISSN 1535-7163, pages 949 - 957, XP093098637-
OPPOSITION- Witold Lasek; Radosław Zagożdżon; Marek Jakobisiak, "Interleukin 12: still a promising candidate for tumor immunotherapy?", Cancer immunology immunotherapy, Berlin/Heidelberg , (20140501), vol. 63, no. 5, doi:10.1007/s00262-014-1523-1, ISSN 0340-7004, pages 419 - 435, XP055656186
OPPOSITION- Witold Lasek; Radosław Zagożdżon; Marek Jakobisiak, "Interleukin 12: still a promising candidate for tumor immunotherapy?", Cancer immunology immunotherapy, Springer, Berlin/Heidelberg, Berlin/Heidelberg , (20140501), vol. 63, no. 5, doi:10.1007/s00262-014-1523-1, ISSN 0340-7004, pages 419 - 435, XP055656186
OPPOSITION- Suzuki, R. ; Namai, E. ; Oda, Y. ; Nishiie, N. ; Otake, S. ; Koshima, R. ; Hirata, K. ; Taira, Y. ; Utoguchi, N. ; Negishi, Y. ; Nakagawa, S. ; Maruyama, K., "Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure", Journal of Controlled Release, AMSTERDAM, NL , (20100303), vol. 142, no. 2, doi:10.1016/j.jconrel.2009.10.027, ISSN 0168-3659, pages 245 - 250, XP026905287
OPPOSITION- Oliwia Andries, Séan Mc Cafferty, Stefaan C. De Smedt, Ron Weiss, Niek N. Sanders, Tasuku Kitada, "N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice", Journal of Controlled Release, AMSTERDAM, NL , (20151101), vol. 217, doi:10.1016/j.jconrel.2015.08.051, ISSN 0168-3659, pages 337 - 344, XP055231071
OPPOSITION- Kauffman Kevin J.; Webber Matthew J.; Anderson Daniel G., "Materials for non-viral intracellular delivery of messenger RNA therapeutics", Journal of Controlled Release, AMSTERDAM, NL , (20151221), vol. 240, doi:10.1016/j.jconrel.2015.12.032, ISSN 0168-3659, pages 227 - 234, XP029759407
OPPOSITION- Hsu Shu-Hao, Yu Bo, Wang Xinmei, Lu Yuanzhi, Schmidt Carl R., Lee Robert J., Lee L. James, Jacob Samson T., Ghoshal Kalpana, "Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor", Nanomedicine, AMSTERDAM, NL, (20131101), vol. 9, no. 8, doi:10.1016/j.nano.2013.05.007, ISSN 1549-9634, pages 1169 - 1180, XP093098659
OPPOSITION- Alex K. K. Leung, Yuen Yi C. Tam, Sam Chen, Ismail M. Hafez, Pieter R. Cullis, "Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems", Journal of Physical Chemistry Part B, US , (20150716), vol. 119, no. 28, doi:10.1021/acs.jpcb.5b02891, ISSN 1520-6106, pages 8698 - 8706, XP055551921
OPPOSITION- Kevin J. Kauffman, J. Robert Dorkin, Jung H. Yang, Michael W. Heartlein, Frank Derosa, Faryal F. Mir, Owen S. Fenton, Daniel G. Anderson, "Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs", Nano Letters, US , (20151111), vol. 15, no. 11, doi:10.1021/acs.nanolett.5b02497, ISSN 1530-6984, pages 7300 - 7306, XP055679418
OPPOSITION- S Tugues, S H Burkhard, I Ohs, M Vrohlings, K Nussbaum, J Vom Berg, P Kulig, B Becher, "New insights into IL-12-mediated tumor suppression", Cell Death & Differentiation, GB , (20150201), vol. 22, no. 2, doi:10.1038/cdd.2014.134, ISSN 1350-9047, pages 237 - 246, XP055285716
OPPOSITION- Anwer K; Barnes M N; Fewell J; Lewis D H; Alvarez R D, "Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer", Gene Therapy, GB , (20091224), vol. 17, no. 3, doi:10.1038/gt.2009.159, ISSN 0969-7128, pages 360 - 369, XP037773216
OPPOSITION- Andreas Thess, Stefanie Grund, Barbara L Mui, Michael J Hope, Patrick Baumhof, Mariola Fotin-Mleczek, Thomas Schlake, "Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals", Molecular Therapy, US , (20150901), vol. 23, no. 9, doi:10.1038/mt.2015.103, ISSN 1525-0016, pages 1456 - 1464, XP055316910
OPPOSITION- G J Lieschke , P K Rao, M K Gately, R C Mulligan, "Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo.", Nature Biotechnology, New York, (19970101), vol. 15., no. 01., doi:10.1038/nbt0197-35, ISSN 1087-0156, pages 35 - 40., XP002106574
OPPOSITION- Ugur Sahin; Katalin Karikó; Özlem Türeci, "mRNA-based therapeutics — developing a new class of drugs", Nature Reviews Drug Discovery, GB , (20141001), vol. 13, no. 10, doi:10.1038/nrd4278, ISSN 1474-1776, pages 759 - 780, XP055544673
OPPOSITION- Chikkanna-Gowda C P; Sheahan B J; Fleeton M N; Atkins G J, "Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12", Gene Therapy, GB , (20050602), vol. 12, no. 16, doi:10.1038/sj.gt.3302561, ISSN 0969-7128, pages 1253 - 1263, XP037773133
OPPOSITION- Holger N. Lode, Rong Xiang, Steven R. Duncan, Argyrios N. Theofilopoulos, Stephen D. Gillies, Ralph A. Reisfeld, "Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12.", Proceedings of the National Academy of Sciences, National Academy of Sciences, (19990720), vol. 96, no. 15, doi:10.1073/pnas.96.15.8591, ISSN 0027-8424, pages 8591 - 8596, XP002224792
OPPOSITION- Lucie Heinzerling , Günter Burg, Reinhard Dummer, Tanja Maier, Patrick A Oberholzer, Jan Schultz, Lina Elzaouk, Jovan Pavlovic, Karin Moelling, "Intratumoral Injection of DNA Encoding Human Interleukin 12 into Patients with Metastatic Melanoma: Clinical Efficacy", Human Gene Therapy, (20050101), vol. 16, no. 1, doi:10.1089/hum.2005.16.35, pages 35 - 48, XP093097153
OPPOSITION- Rodriguez-Madoz Juan R., Zabala Maider, Alfaro Maite, Prieto Jesus, Kramer M. Gabriela, Smerdou Cristian, "Short-Term Intratumoral Interleukin-12 Expressed from an Alphaviral Vector Is Sufficient to Induce an Efficient Antitumoral Response Against Spontaneous Hepatocellular Carcinomas", Human Gene Therapy, GB , (20140201), vol. 25, no. 2, doi:10.1089/hum.2013.080, ISSN 1043-0342, pages 132 - 143, XP093098645
OPPOSITION- Brigitte M. Pützer, Thorsten Stiewe, Florian Rödicker, Oliver Schildgen, Stefan Rühm, Olaf Dirsch, Melanie Fiedler, Uta Damen, Bud Tennant, Caren Scherer, Frank L. Graham, Michael Roggendorf, "Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes.", Journal of the National Cancer Institute, GB , (20010321), vol. 93, no. 6, doi:10.1093/jnci/93.6.472, ISSN 0027-8874, pages 472 - 479, XP002421568
OPPOSITION- Chengyong Jiang, D. Mitchell Magee, Rebecca A. Cox, "Construction of a Single-Chain Interleukin-12-Expressing Retroviral Vector and Its Application in Cytokine Gene Therapy against Experimental Coccidioidomycosis", Infection and Immunity, United States, (19990601), vol. 67, no. 6, doi:10.1128/iai.67.6.2996-3001.1999, pages 2996 - 3001, XP055351282
OPPOSITION- José I Quetglas; Sara Labiano; Ángela Aznar M; Elixabet Bolaños; Arantza Azpilikueta; Inmaculada Rodriguez; Erkuden Casales; Alfonso R Sánchez-Paulete; Víctor Segura; Cristian Smerdou; Ignacio Melero, "Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade", Cancer Immunology Research, US , (20150501), vol. 3, no. 5, doi:10.1158/2326-6066.CIR-14-0216, ISSN 2326-6066, pages 449 - 454, XP055576398
OPPOSITION- K.-J. Kallen, A. Thess, "A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs", Therapeutic Advances in Vaccines, (20140101), vol. 2, no. 1, doi:10.1177/2051013613508729, ISSN 20510136, pages 10 - 31, XP055126338
OPPOSITION- Wulff Holger; Krieger Thorsten; Krüger Karen; Stahmer Ingrid; Thaiss Friedrich; Schäfer Hansjörg; Block Andreas, "Cloning and characterization of an adenoviral vector for highly efficient and doxycycline - suppressible expression of bioactive human single - chain interleukin 12 in colon cancer", BMC Biotechnology, (20070626), vol. 7, no. 1, doi:10.1186/1472-6750-7-35, ISSN 1472-6750, pages 1 - 9, XP021029475
OPPOSITION- Somayeh Hallaj-Nezhadi, Lotfipour Farzaneh, Dass Crispin, "Nanoparticle-Mediated Interleukin-12 Cancer Gene Therapy", Journal of pharmacy & pharmaceutical sciences, Canada , (20100101), vol. 13, no. 3, doi:10.18433/J3630V, pages 472 - 485, XP055739905
OPPOSITION- Hernandez-Alcoceba Ruben; Poutou Joanna; Cristina Ballesteros-Briones Maria; Smerdou Cristian, "Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12", Immunotherapy, GB , (20160101), vol. 8, no. 2, doi:10.2217/imt.15.109, ISSN 1750-743X, pages 179 - 198, XP009502991
OPPOSITION- Andreas M Reichmuth, Matthias A Oberli, Ana Jaklenec, Robert Langer, Daniel Blankschtein, "mRNA vaccine delivery using lipid nanoparticles", Therapeutic Delivery, GB , (20160501), vol. 7, no. 5, doi:10.4155/tde-2016-0006, ISSN 2041-5990, pages 319 - 334, XP055401839

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents